MabVax Therapeutics

MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company specializing in the discovery and rapid clinical development of fully human antibodies aimed at addressing unmet medical needs in cancer treatment. The company's core product, MVT-5873, is a fully human IgG1 monoclonal antibody targeting sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials for pancreatic cancer and other CA19-9 positive tumors. MabVax collaborates with renowned institutions such as Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health, and Imaging Endpoints. To date, 50 patients have been treated with either MVT-5873 or the PET imaging diagnostic product MVT-2163 in Phase 1 clinical studies, demonstrating early safety, target specificity, and potential efficacy. The company has also commenced patient dosing for its radioimmunotherapy product MVT-1075 in a Phase 1 clinical study. MabVax operates in the biotechnology sector, primarily serving the oncology market, and generates revenue through the development and potential commercialization of its antibody-based therapies.

Keywords: biotechnology, antibodies, cancer treatment, clinical trials, pancreatic cancer, monoclonal antibody, CA19-9, oncology, radioimmunotherapy, PET imaging.